You are here: Home » PTI Stories » National » News
Business Standard

Eris Lifesciences IPO subscribed 12% on Day 1

Press Trust of India  |  New Delhi 

The initial public offer of Eris Lifesciences was subscribed 12 per cent on the first day of bidding today.

The IPO, to raise Rs 1,741 crore, received bids for 18,55,728 against the total issue size of 1,59,48,750 shares, as per data available with the till 1815 hours.



The portion set aside for qualified institutional buyers (QIBs) was subscribed 7 per cent, non-institutional investors 2 per cent and retail investors 41 per cent.

Eris Lifesciences yesterday mopped up Rs 779 crore from 21 anchor investors.

The price band for the share sale has been fixed at Rs 600-603.

The offer, which closes on June 20, comprises sale of 2.89 crore

The book Running Lead Managers to the offer are Axis Capital, Citigroup and Credit Suisse Securities (India).

Eris Lifesciences is into manufacturing of branded pharmaceutical products in select therapeutic areas.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Eris Lifesciences IPO subscribed 12% on Day 1

The initial public offer of Eris Lifesciences was subscribed 12 per cent on the first day of bidding today. The IPO, to raise Rs 1,741 crore, received bids for 18,55,728 shares against the total issue size of 1,59,48,750 shares, as per data available with the NSE till 1815 hours. The portion set aside for qualified institutional buyers (QIBs) was subscribed 7 per cent, non-institutional investors 2 per cent and retail investors 41 per cent. Eris Lifesciences yesterday mopped up Rs 779 crore from 21 anchor investors. The price band for the share sale has been fixed at Rs 600-603. The offer, which closes on June 20, comprises sale of 2.89 crore shares. The book Running Lead Managers to the offer are Axis Capital, Citigroup Global Markets India and Credit Suisse Securities (India). Eris Lifesciences is into manufacturing of branded pharmaceutical products in select therapeutic areas. The initial public offer of Eris Lifesciences was subscribed 12 per cent on the first day of bidding today.

The IPO, to raise Rs 1,741 crore, received bids for 18,55,728 against the total issue size of 1,59,48,750 shares, as per data available with the till 1815 hours.

The portion set aside for qualified institutional buyers (QIBs) was subscribed 7 per cent, non-institutional investors 2 per cent and retail investors 41 per cent.

Eris Lifesciences yesterday mopped up Rs 779 crore from 21 anchor investors.

The price band for the share sale has been fixed at Rs 600-603.

The offer, which closes on June 20, comprises sale of 2.89 crore

The book Running Lead Managers to the offer are Axis Capital, Citigroup and Credit Suisse Securities (India).

Eris Lifesciences is into manufacturing of branded pharmaceutical products in select therapeutic areas.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Eris Lifesciences IPO subscribed 12% on Day 1

The initial public offer of Eris Lifesciences was subscribed 12 per cent on the first day of bidding today.

The IPO, to raise Rs 1,741 crore, received bids for 18,55,728 against the total issue size of 1,59,48,750 shares, as per data available with the till 1815 hours.

The portion set aside for qualified institutional buyers (QIBs) was subscribed 7 per cent, non-institutional investors 2 per cent and retail investors 41 per cent.

Eris Lifesciences yesterday mopped up Rs 779 crore from 21 anchor investors.

The price band for the share sale has been fixed at Rs 600-603.

The offer, which closes on June 20, comprises sale of 2.89 crore

The book Running Lead Managers to the offer are Axis Capital, Citigroup and Credit Suisse Securities (India).

Eris Lifesciences is into manufacturing of branded pharmaceutical products in select therapeutic areas.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22